AMRZ vs LIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits a Piotroski F-Score of 4/9, indicating stable but not robust financial health, while the absence of an Altman Z-Score limits distress risk assessment. Valuation metrics suggest the stock trades at a premium to both the Graham Number ($35.19) and intrinsic value ($16.52), supported by a high P/E of 22.98 versus sector peers. Despite solid operating margins and manageable leverage, earnings growth is negative year-over-year and quarterly earnings surprises have been inconsistent. Analysts recommend a 'buy' with a target price of $60.08, implying upside, but weak recent price performance and lack of dividend or insider activity temper near-term conviction.
LIN shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AMRZ vs LIN: Head-to-Head Comparison
This page compares Amrize Ltd (AMRZ) and Linde plc (LIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.